New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
White will be the first person living with CF to lead the Board into a new era of CF
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance